Lexicon Pharmaceuticals (LXRX) Operating Leases (2022 - 2024)

Lexicon Pharmaceuticals (LXRX) has reported Operating Leases for 3 consecutive years, with $6.4 million the latest figure, recorded in Q1 2024.

• In Q1 2024, Operating Leases changed N/A year-over-year to $6.4 million; the TTM figure through Mar 2024 stood at $6.4 million (changed N/A YoY), while the FY2023 annual figure was $5.3 million, down 2.93% from the prior year.
• Operating Leases rose to $6.4 million in Q1 2024 per LXRX's latest filing, from $5.3 million in the prior quarter.
• Across five years, Operating Leases topped out at $6.4 million in Q1 2024 and bottomed at $5.3 million in Q4 2023.
• Historically, Operating Leases has averaged $5.6 million across 3 years, with a median of $5.4 million in 2022.
• On a YoY basis, Operating Leases climbed as much as 2.93% in 2023 and fell as far as 2.93% in 2023.
• Lexicon Pharmaceuticals' Operating Leases stood at $5.4 million in 2022, then retreated by 2.93% to $5.3 million in 2023, then rose by 20.99% to $6.4 million in 2024.
• Business Quant data shows LXRX's Operating Leases at $6.4 million in Q1 2024, $5.3 million in Q4 2023, and $5.4 million in Q3 2023.